Skip to main content

Advertisement

SpringerLink
Log in

Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer

  • Case Report
  • Published:
Osteoporosis International Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 01 July 2022

Abstract

Denosumab delays and prevents skeletal related events in patients with malignancy-related bony metastases. Rarely, denosumab discontinuation can lead to rebound hypercalcemia in the setting of increased bone resorption. We describe the case of a 49-year-old breast cancer survivor who developed rebound hypercalcemia after cessation of long-term denosumab. She had been treated with 42 doses of denosumab between August 2013 and March 2020 and 8 months after her last dose of denosumab developed symptomatic hypercalcemia. Parathyroid hormone levels were suppressed, and active malignancy was excluded based on biochemical and radiological testing. She required treatment with intravenous bisphosphonates on three separate occasions in order to achieve long-term normalization of her hypercalcemia. Rebound hypercalcemia post-denosumab cessation is a rare but serious complication that clinicians should be aware of.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 352(4):373–9. https://doi.org/10.1056/NEJMcp042806

    Article  CAS  PubMed  Google Scholar 

  2. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139. https://doi.org/10.1200/JCO.2010.29.7101

    Article  CAS  PubMed  Google Scholar 

  3. Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10(1):152. https://doi.org/10.3390/jcm10010152

    Article  CAS  PubMed Central  Google Scholar 

  4. Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B (2017) role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol 35(35):3978–3986. https://doi.org/10.1200/JCO.2017.75.4614

    Article  CAS  PubMed  Google Scholar 

  5. Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K, ESMO Guidelines Committee (2020) Electronic address: clinicalguidelines@esmo.org. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31(12):1650–1663. https://doi.org/10.1016/j.annonc.2020.07.019

  6. Camponovo C, Aubry-Rozier B, Lamy O, Gonzalez RE (2020) Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporos Int 31(12):2485–2491. https://doi.org/10.1007/s00198-020-05676-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Maugars Y, Guillot P, Glémarec J, Berthelot JM, Le Goff B, Darrieutort-Laffite C (2020) Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report. J Med Case Rep 14(1):130. https://doi.org/10.1186/s13256-020-02401-0

    Article  PubMed  PubMed Central  Google Scholar 

  8. Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, Sutton D, Grimer R, Högler W (2018) Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab 103(2):596–603. https://doi.org/10.1210/jc.2017-02025

    Article  PubMed  Google Scholar 

  9. Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E (2019) Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 20(12):1719–1729. https://doi.org/10.1016/S1470-2045(19)30663-1

    Article  CAS  PubMed  Google Scholar 

  10. Uchida T, Yamaguchi H, Kushima C, Yonekawa T, Nakazato M (2020) Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab. Endocr J 67(1):31–35. https://doi.org/10.1507/endocrj.EJ19-0198

    Article  PubMed  Google Scholar 

  11. Roux S, Massicotte MH, Huot Daneault A, Brazeau-Lamontagne L, Dufresne J (2019) Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: case report and brief literature review. Bone 120:482–486. https://doi.org/10.1016/j.bone.2018.12.012

    Article  PubMed  Google Scholar 

  12. Koldkjær Sølling AS, Harsløf T, Kaal A, Rejnmark L, Langdahl B (2016) Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int 27(7):2383–2386. https://doi.org/10.1007/s00198-016-3535-5

    Article  CAS  PubMed  Google Scholar 

  13. Tjelum L, Eiken P (2018) [Multiple vertebral fractures after denosumab discontinuation]. Ugeskr Laeger. 180(45):V12170948. Danish

  14. Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, Bassim C, Cherman N, Ellsworth M, Kasa-Vubu JZ, Farley FA, Molinolo AA, Bhattacharyya N, Collins MT (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27(7):1462–1470. https://doi.org/10.1002/jbmr.1603

    Article  CAS  PubMed  Google Scholar 

  15. Grasemann C, Schündeln MM, Hövel M, Schweiger B, Bergmann C, Herrmann R, Wieczorek D, Zabel B, Wieland R, Hauffa BP (2013) Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab 98(8):3121–3126. https://doi.org/10.1210/jc.2013-1143

    Article  CAS  PubMed  Google Scholar 

  16. Gossai N, Hilgers MV, Polgreen LE, Greengard EG (2015) Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer 62(6):1078–1080. https://doi.org/10.1002/pbc.25393

    Article  PubMed  Google Scholar 

  17. Setsu N, Kobayashi E, Asano N, Yasui N, Kawamoto H, Kawai A, Horiuchi K (2016) Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab 34(1):118–122. https://doi.org/10.1007/s00774-015-0677-z

    Article  PubMed  Google Scholar 

  18. Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O (2016) Safety and efficacy of denosumab in children with osteogenesis imperfect–a first prospective trial. J Musculoskelet Neuronal Interact 16(1):24–32

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Trejo P, Rauch F, Ward L (2018) Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 18(1):76–80

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Dürr HR, Grahneis F, Baur-Melnyk A, Knösel T, Birkenmaier C, Jansson V, Klein A (2019) Aneurysmal bone cyst: results of an off label treatment with Denosumab. BMC Musculoskelet Disord 20(1):456. https://doi.org/10.1186/s12891-019-2855-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Upfill-Brown A, Bukata S, Bernthal NM, Felsenfeld AL, Nelson SD, Singh A, Wesseling-Perry K, Eilber FC, Federman NC (2019) Use of denosumab in children with osteoclast bone dysplasias: report of three cases. JBMR Plus 3(10):e10210. https://doi.org/10.1002/jbm4.10210

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11–17. https://doi.org/10.1016/j.bone.2017.08.003

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetes and Endocrinology, Peninsula Health, 2 Hastings Road, Frankston, VIC, 3199, Australia

    R. Wang & D. A. Renouf

Authors
  1. R. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. A. Renouf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Wang.

Ethics declarations

Conflict of interest

None.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, R., Renouf, D.A. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer. Osteoporos Int 33, 1625–1629 (2022). https://doi.org/10.1007/s00198-022-06369-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-022-06369-z

Keywords

Search

Navigation